Japan's Ministry of Health, Labour and Welfare has approved Myriad Genetics' BRACAnalysis Diagnostic System to help physicians determine which women with breast cancer have Hereditary Breast and Ovarian Cancer syndrome and qualify for additional medical management.
Men who seek treatment at a multidisciplinary prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines, an MD Anderson Cancer Center study found.
Within a cohort of 106,732 cancer survivors diagnosed between 2000 and 2015, researchers at the University of California San Diego determined rates of persistent post-treatment opioid use, diagnoses of opioid abuse or dependence, and admissions for opioid toxicity.
A statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose whose tumors expressed PD-L1 <1%, according to results from phase III CheckMate -915.
Ethan Basch, director of the Cancer Outcomes Research Program and professor of hematology and oncology at UNC Lineberger Comprehensive Cancer Center, received the Association of Community Cancer Centers 2019 Clinical Research Award.
Harmar BreretonDana DornsiferHarmar Brereton and Dana Dornsife received the National Coalition for Cancer Survivorship's Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care Nov. 13.
Cardiothoracic surgeon Timothy W. Mullett was named chair-elect of the Commission on Cancer of the American College of Surgeons during the CoC's annual meeting Oct. 27 in San Francisco.
Roswell Park received more than $21.8 million in recent competitive grants and contracts to launch new investigations or continue major research efforts. This includes funding from NCI's Cancer Moonshot program as well as renewals for high-impact projects based at Roswell Park.
Bristol-Myers Squibb Co. has completed its acquisition of Celgene Corp. following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, approval by Bristol-Myers Squibb and Celgene stockholders. It completed the acquisition Nov. 20.
Questions on flavored vaping products dominated the Nov. 20 Senate confirmation hearing for Stephen M. Hahn, the administration's pick for the job of FDA commissioner.
